Exelixis | EXEL - Ingresos Por Ventas





Ventas Cambio Fecha
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Amgen USD 10.1B 1.48B 2026-06
AstraZeneca USD 15.38B 90M 2026-06
Bayer EUR 10.87B 2.54B 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Cytokinetics USD 28.6M 9.25M 2026-06
Eisai JPY 234.33B 28.9B 2026-06
Eli Lilly USD 22.97B 3.17B 2026-06
Exelixis USD 628.69M 17.89M 2026-06
Genmab DKK 1.16B 259M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.6B 310M 2026-06
Moderna USD 100M 289M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 15.03B 530M 2026-06
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sanofi EUR 12.14B 65M 2026-03
Takeda JPY 1.22T 130B 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Xencor USD 51.22M 46.71M 2026-06